Real Endpoints board member Michael Sherman spells out the implications of recent Massachusetts-based GLP-1 coverage decisions for different healthcare stakeholders. Thing is these implications could also easily apply to any number of drugs in other competitive disease spaces, where there is high budget impact and more than a little uncertainty about clinical benefit.
read full article ›Sanofi’s $9B acquisition of Blueprint Medicines brings a welcome burst of heat to biotech’s long dealmaking winter. And it offers a few clear reminders about how access and reimbursement shape commercial value today.
read full article ›Thanks to the team at SwissHLG for inviting our CEO Jeff Berkowitz to discuss how early stage biotechs - and the investors who fund them - should invest in critical market access capabilities to drive commercial success.
read full article ›President Trump today signed an Executive order that, despite the pomp and circumstance, provided little to no detail on how it would be carried out. As expected, the order highlights Trump’s intent to use a “Most Favored Nation” strategy, in which U.S. prices will be tied to the lowest drug prices paid by developed countries.
read full article ›And we are off and running at Asembia 2025. If you would like to talk market access, product reimbursement, or patient assistance, the Real Endpoints team still has some open spots to meet April 27, 28, and 29. Connect with us via a direct message or email @info@realendpoints.com.
read full article ›This month brought a wave of healthcare news—from leadership changes at HHS and FDA staff reductions to the finalized Medicare Advantage rule and ongoing concerns around pharmaceutical tariffs. Amid the shifting landscape, one issue remains consistent: many patients continue to face high out-of-pocket drug costs. According to the Commonwealth Fund, 43% of working adults are under-insured, and nearly half of Medicare beneficiaries struggle with co-pays. Solutions like RE Assist, an AI-supported platform and 2024 Fierce Healthcare Innovation awardee, aim to help address this gap by connecting patients with financial support resources.
read full article ›Thanks to LifeScience ORG for the opportunity for Real Endpoints' Jeff Berkowitz to talk about US market access and payer trends with Gregory Oakes!
read full article ›Super excited that our Real Endpoints team will be onsite at to discuss supporting patient access and our award-winning platform RE Assist.
read full article ›We are so excited to welcome Emma Frohnapfel to Real Endpoints as a Client Service Manager! Emma brings a wealth of data and operational expertise from her training at Clemson University, her ongoing graduate studies, and past internships. She will be a critical resource supporting a range of projects spanning our patient support work and more bespoke projects linked to market access.
read full article ›